Afficher la notice abrégée

Modeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin

hal.structure.identifierIowa State University [ISU]
dc.contributor.authorSCHNEIDER, Benjamin
hal.structure.identifierAssistance Publique - Hôpitaux de Marseille [APHM]
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorBOYER, Arnaud
hal.structure.identifierSimulation and Modeling of Adaptive Response for Therapeutics in Cancer [SMARTc]
dc.contributor.authorCICCOLINI, Joseph
hal.structure.identifierMayo Clinic [Rochester]
dc.contributor.authorWANG, Kenneth
hal.structure.identifierMayo Clinic [Rochester]
dc.contributor.authorFERNANDEZ-ZAPICO, Martin E
hal.structure.identifierIowa State University [ISU]
dc.contributor.authorMOCHEL, Jonathan
hal.structure.identifierInstitut de Mathématiques de Bordeaux [IMB]
hal.structure.identifierModélisation Mathématique pour l'Oncologie [MONC]
dc.contributor.authorBENZEKRY, Sébastien
dc.date.accessioned2024-04-04T03:02:37Z
dc.date.available2024-04-04T03:02:37Z
dc.date.issued2018-05
dc.date.conference2018-05-29
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/193003
dc.description.abstractEnSituation: Bevacizumab is an anti-angiogenic drug commonly administered contaminantly with chemotherapeutic drugs for advanced non- squamous non-small cell lung cancer (NSCLC). Bevacizumab administration transiently enhances chemotherapeutic drug delivery, resulting in increased efficacy of chemotherapeutic drugs.Objective: This analysis attempts to characterize tumor growth dynamics as measured by uorescence in response to concurrent vs. sequential administration of pemetrexed-cisplatin and bevacizumab in NSCLC tumor carrying mice.Methods:Experiment: Data comes from previous experiment where 77 mice were randomized into 5 treatment groups:i) control (saline, N=15),ii) beva then pemetrexed-cisplatan after 3 daysiii) beva then pemetrexed-cisplatan after 8 days iv) concomitant beva + pemetrexed-cisplatanv) pemetrexed cisplatin aloneStatistical Analysis: Tumor size was evaluated by uorescence and the resulting data were analyzed using the stochastic approximation expectation maximization algorithm implemented in Monolix 2018 R1. Standard model diagnostics were completed using various R packages as well as other components of the Monolix Suite.
dc.language.isoen
dc.title.enModeling Primary Tumor Dynamics of Human-to-Mouse Xenografted Non-Small Cell Lung Cancer in Response to Administration of Bevacizumab and Pemetrexed-Cisplatin
dc.typeAutre communication scientifique (congrès sans actes - poster - séminaire...)
dc.subject.halSciences du Vivant [q-bio]/Cancer
dc.subject.halInformatique [cs]/Modélisation et simulation
dc.subject.halStatistiques [stat]/Applications [stat.AP]
dc.subject.halSciences du Vivant [q-bio]/Sciences pharmaceutiques/Médicaments
dc.subject.halSciences du Vivant [q-bio]
bordeaux.hal.laboratoriesInstitut de Mathématiques de Bordeaux (IMB) - UMR 5251*
bordeaux.institutionUniversité de Bordeaux
bordeaux.institutionBordeaux INP
bordeaux.institutionCNRS
bordeaux.conference.titlePopulation Approach Group in Europe (PAGE) Meeting 2018
bordeaux.countryCH
bordeaux.conference.cityMontreux
bordeaux.peerReviewedoui
hal.identifierhal-01968942
hal.version1
hal.invitednon
hal.proceedingsnon
hal.conference.end2018-06-01
hal.popularnon
hal.audienceInternationale
hal.origin.linkhttps://hal.archives-ouvertes.fr//hal-01968942v1
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.date=2018-05&rft.au=SCHNEIDER,%20Benjamin&BOYER,%20Arnaud&CICCOLINI,%20Joseph&WANG,%20Kenneth&FERNANDEZ-ZAPICO,%20Martin%20E&rft.genre=conference


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée